Physician profile
Reena Thomas
NPI 1366672834
$5,766.14
in general payments reported to CMS, 2019-2025
34 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.70 · 2021: $187 · 2022: $1,210 · 2023: $1,357 · 2024: $1,354 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,345.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $833.65 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $808.45 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Amgen INC. | $541.28 | 2022-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $435.51 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $428.67 | 2022-2025 | |
| Lilly USA, LLC | $337.49 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $316.44 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $301.99 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $221.00 | 2022-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Janssen Pharmaceuticals, INC | $200.89 | 2021-2023 | Xarelto |
| Sumitomo Pharma America, INC. | $177.64 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $177.22 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $131.63 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $93.14 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $92.92 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $92.50 | 2022-2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.10 | 2024-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $70.74 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $59.79 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.82 | 2022 | |
| Corcept Therapeutics | $40.96 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $34.61 | 2025 | |
| Viatris Specialty LLC | $34.50 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $33.39 | 2022-2023 | Quviviq |
| Eisai INC. | $26.07 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $22.84 | 2023 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.70 | 2020 | |
| Renalytix Ai, INC. | $19.13 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Grt US Holding, INC. | $17.11 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.90 | 2025 | Gvoke Hypopen |
| Azurity Pharmaceuticals, INC. | $14.50 | 2023 | Adthyza |
| Seqirus USA INC | $13.62 | 2021 | |
| Philips North America LLC | $13.31 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.